249 related articles for article (PubMed ID: 35433454)
1. BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective.
Yan N; Guo S; Zhang H; Zhang Z; Shen S; Li X
Front Oncol; 2022; 12():863043. PubMed ID: 35433454
[TBL] [Abstract][Full Text] [Related]
2. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.
Turshudzhyan A; Vredenburgh J
Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review.
Puri M; Gawri K; Dawar R
Front Oncol; 2023; 13():1141876. PubMed ID: 37645429
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study.
Wang W; Gu X; Si J; Pu X; Wang L; Chen H; Xu C; Zhang X; Yuan H; Lou G; Shao L; Zhang G; Song Z
Genes Chromosomes Cancer; 2022 Sep; 61(9):530-541. PubMed ID: 35396765
[TBL] [Abstract][Full Text] [Related]
5. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced
Xue Y; Ren Y; Yan B; Li Z; Huang C
Ann Transl Med; 2022 Sep; 10(18):1029. PubMed ID: 36267742
[TBL] [Abstract][Full Text] [Related]
6. Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer.
Li H; Zhang Y; Xu Y; Huang Z; Cheng G; Xie M; Zhou Z; Yu Y; Xi W; Fan Y
Cell Death Dis; 2022 Dec; 13(12):1064. PubMed ID: 36543792
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
8. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
Nguyen-Ngoc T; Bouchaab H; Adjei AA; Peters S
J Thorac Oncol; 2015 Oct; 10(10):1396-403. PubMed ID: 26301799
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg M; Preuß C; Roeper J; Metzenmacher M; Eberhardt W; Stropiep U; Wedeken K; Reis H; Herold T; Darwiche K; Aigner C; Stuschke M; Schildhaus HU; Schmid KW; Falk M; Heukamp L; Tiemann M; Griesinger F; Schuler M
Eur J Cancer; 2021 May; 149():211-221. PubMed ID: 33872981
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
11. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S;
Cancer Treat Rev; 2022 Feb; 103():102335. PubMed ID: 35033867
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Guisier F; Dubos-Arvis C; Viñas F; Doubre H; Ricordel C; Ropert S; Janicot H; Bernardi M; Fournel P; Lamy R; Pérol M; Dauba J; Gonzales G; Falchero L; Decroisette C; Assouline P; Chouaid C; Bylicki O
J Thorac Oncol; 2020 Apr; 15(4):628-636. PubMed ID: 31945494
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
Nagano T; Tachihara M; Nishimura Y
Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458
[TBL] [Abstract][Full Text] [Related]
14. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Joshi M; Rice SJ; Liu X; Miller B; Belani CP
PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
[TBL] [Abstract][Full Text] [Related]
15. [Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation
in Non-small Cell Lung Cancer].
Liu X; Zhong D
Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):583-589. PubMed ID: 31526463
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring
Wang H; Cheng L; Zhao C; Zhou F; Jiang T; Guo H; Shi J; Chen P; Tang Z; Mao S; Jia K; Ye L; Cai C; Li X; Chen X; Zhou C
Transl Lung Cancer Res; 2023 Feb; 12(2):219-229. PubMed ID: 36895926
[TBL] [Abstract][Full Text] [Related]
17. [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant
Advanced Non-small Cell Lung Cancer].
Li N; Xu Y; Fan Y
Zhongguo Fei Ai Za Zhi; 2021 Oct; 24(10):714-722. PubMed ID: 34696543
[TBL] [Abstract][Full Text] [Related]
18. Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.
Ito T; Nagashima H; Akiyama M; Utsumi Y; Sato H; Chiba S; Sugai M; Ube K; Mori Y; Watanabe K; Fukuhara T; Maemondo M
Thorac Cancer; 2022 Feb; 13(3):386-393. PubMed ID: 34904383
[TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.
Qu J; Shen Q; Li Y; Kalyani FS; Liu L; Zhou J; Zhou J
Front Oncol; 2022; 12():911303. PubMed ID: 35814395
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
